1. Academic Validation
  2. Biphenyl Acid Derivatives as APJ Receptor Agonists

Biphenyl Acid Derivatives as APJ Receptor Agonists

  • J Med Chem. 2019 Nov 27;62(22):10456-10465. doi: 10.1021/acs.jmedchem.9b01513.
Shun Su 1 Adam Clarke 1 Ying Han 1 Hannguang J Chao 1 Jeffrey Bostwick 1 William Schumacher 1 Tao Wang 1 Mujing Yan 1 Mei-Yin Hsu 1 Eric Simmons 1 Chiuwa Luk 1 Carrie Xu 1 Marta Dabros 1 Michael Galella 1 Joelle Onorato 1 David Gordon 1 Ruth Wexler 1 Peter S Gargalovic 1 R Michael Lawrence 1
Affiliations

Affiliation

  • 1 Research and Development , Bristol-Myers Squibb, Co. , P.O. Box 5400, Princeton , New Jersey 08543-5400 , United States.
Abstract

The APJ receptor and its endogenous peptidic ligand apelin have been implicated as important modulators of cardiovascular function, and APJ receptor agonists may be beneficial in the treatment of heart failure. In this article, we describe the discovery of a series of biphenyl acid derivatives as potent APJ receptor agonists. Following the identification of initial high-throughput screen lead 2, successive optimization led to the discovery of lead compound 15a. Compound 15a demonstrated comparable in vitro potency to apelin-13, the endogenous peptidic ligand for the APJ receptor. In vivo, compound 15a demonstrated a dose-dependent improvement in the cardiac output in male Sprague Dawley rats with no significant changes in either mean arterial blood pressure or heart rate, consistent with the hemodynamic profile of apelin-13 in an acute pressure volume loop model.

Figures
Products